Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD99-A192
- Development stage
- Preclinical
- Lead developer
- University of Southern California
- Modality
- scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
01
Overview
anti-CD99-A192 is a therapeutic nanoparticle composed of a single-chain variable fragment (scFv) targeting CD99 fused to elastin-like polypeptides (ELPs). Developed by researchers at the University of Southern California, it is designed to treat acute myeloid leukemia (AML). The drug exhibits a dual mechanism of action: it directly targets and induces apoptosis in CD99-overexpressing leukemic cells and simultaneously acts as an immunomodulator by stimulating T cell proliferation and activation. This activation is characterized by increased expression of CD38 and the release of pro-inflammatory cytokines such as TNF-α and IL-1β, which enhances the cytotoxic response against AML cells.
- Other names
- anti-CD99-A192 scFv-ELP nanoparticleanti-CD-99-A192 scFv-ELP nanoparticleanti-CD 99-A192 scFv-ELP nanoparticle
02
Targets
CD99 (CD99 molecule)
Beyond the preview
Go deeper on anti-CD99-A192.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD99-A192.